|
| Index | - | P/E | - | EPS (ttm) | -2.02 | Insider Own | 0.10% | Shs Outstand | 24.72M | Perf Week | 8.90% |
| Market Cap | 335.70M | Forward P/E | - | EPS next Y | -2.21 | Insider Trans | 0.00% | Shs Float | 18.38M | Perf Month | 13.07% |
| Income | -48.70M | PEG | - | EPS next Q | -0.69 | Inst Own | 39.20% | Short Float | 4.41% | Perf Quarter | 6.84% |
| Sales | 22.60M | P/S | 14.85 | EPS this Y | 22.10% | Inst Trans | 27.67% | Short Ratio | 7.29 | Perf Half Y | 0.44% |
| Book/sh | 5.52 | P/B | 2.46 | EPS next Y | 20.50% | ROA | - | Target Price | 19.25 | Perf Year | - |
| Cash/sh | 5.82 | P/C | 2.33 | EPS next 5Y | - | ROE | - | 52W Range | 8.80 - 19.67 | Perf YTD | 20.71% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -29.70% | 52W High | -30.96% | Beta | - |
| Dividend % | - | Quick Ratio | 14.90 | Sales past 5Y | - | Gross Margin | 20.00% | 52W Low | 54.32% | ATR | 0.92 |
| Employees | 87 | Current Ratio | 15.10 | Sales Q/Q | 154.30% | Oper. Margin | - | RSI (14) | 58.97 | Volatility | 7.52% 7.33% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 1.17 | Prev Close | 13.62 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | May 05 AMC | Payout | - | Avg Volume | 111.18K | Price | 13.58 |
| Recom | 1.60 | SMA20 | 13.25% | SMA50 | 10.56% | SMA200 | 9.74% | Volume | 131,354 | Change | -0.29% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite